Exploring and bypassing resistance to targeted therapies in colorectal cancer

Colorectal cancer (CRC) remains a leading cause of cancer-related deaths globally, though targeted therapies have transformed treatment and brought renewed hope. However, resistance to these therapies is a persistent challenge, driven by genetic mutations, epigenetic changes, tumor microenvironment (TME) adaptations, and disruptions in key signaling pathways. These mechanisms allow tumor cells to evade treatment, causing disease progression and limiting long-term success. This review highlights recent breakthroughs and innovative strategies aimed at overcoming resistance in CRC. A deeper understanding of tumor heterogeneity, exosome-mediated communication, and the evolving TME is central to this effort. Promising approaches include biomarker-guided combination therapies and the use of epigenetic modulators to disrupt resistance mechanisms and restore treatment efficacy. Emerging studies also reveal the vulnerabilities of cancer persister cells. Targeting these cells, along with addressing cell cycle dysregulation and DNA damage repair (DDR) pathways, offers new opportunities for durable responses. This review serves as a roadmap for tackling resistance in CRC, with the ultimate goal of improving patient outcomes.